Postpartum depression, or PPD in short, is a serious mood disorder affecting nearly 1 in 7 new mothers, causing intense sadness, anxiety, exhaustion, feelings of worthlessness, and even anger after childbirth (Source: PostpartumDepression.org). While Sage Therapeutics' Zurzuvae is currently the only FDA-approved oral treatment for PPD, conventional therapies like psychotherapy and antidepressants are still widely used off-label.
The stock we are bringing to your attention today is Lipocine Inc. (LPCN), which is developing an oral drug for the treatment of postpartum depression.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.